FindTrial
Sign In

HER-2/neu biomarker expression in pre cancerous and cancerous lesions of uterus cervix

HER-2/neu expression in Premalignant and Malignant epithelial lesions of Uterine Cervix-A cross sectional study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/11/047316
Enrollment
72
Registered
2022-11-15
Start date
Unknown
Completion date
Unknown
Last updated
2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C539- Malignant neoplasm of cervix uteri, unspecified

Interventions

Control Intervention1: Nil: Nil

Sponsors

Rohilkhand Medical College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All histologically diagnosed cases of premalignant and malignant epithelial lesions of cervix received in Department of Pathology in Rohilkhand Medical College and Hospital during study period.

Exclusion criteria

Exclusion criteria: All histologically proven cases of inflammatory, benign lesions and stromal tumors of uterine cervix; inadequate biopsy specimen; patients already on treatment.

Design outcomes

Primary

MeasureTime frame
Immunohistochemical expression of HER-2/neu in premalignant and malignant epithelial lesions of uterine cervix.Timepoint: Baseline investigation—

Secondary

MeasureTime frame
NilTimepoint: Nil—

Countries

India

Contacts

Public ContactDr Nitesh Mohan

Rohilkhand Medical College and Hospital, Bareilly.

simonaranjan31@gmail.com9667301161

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026